Search company, investor...

Cardax Pharmaceuticals

cardaxpharma.com

Founded Year

2006

Stage

Reverse Merger | IPO

Total Raised

$2.86M

Market Cap

0.00B

Stock Price

0.00

About Cardax Pharmaceuticals

Cardax Pharmaceuticals is developing a platform of proprietary small molecule compounds for unmet medical needs where oxidative stress and inflammation play causative roles. The company's platform includes CDX-085 with application in metabolic syndrome, arthritis, and cardiovascular disease, as well as other prodrugs for macular degeneration and prostate disease.

Headquarters Location

2800 Woodlawn Drive Suite 129

Honolulu, Hawaii, 96822,

United States

808-457-1375

Missing: Cardax Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cardax Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cardax Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardax Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cardax Pharmaceuticals Patents

Cardax Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Blood tests
  • Diabetes
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/19/2013

11/10/2015

Carotenoids, Complement system, Inflammations, Cyclohexenes, Fatty acids

Grant

Application Date

6/19/2013

Grant Date

11/10/2015

Title

Related Topics

Carotenoids, Complement system, Inflammations, Cyclohexenes, Fatty acids

Status

Grant

Latest Cardax Pharmaceuticals News

Plant Derivative Drugs Market Emerging Opportunities, Revenue Analysis and Growth Projections 2021-2028 | Cardax Pharmaceuticals, Chi-Med, Chong Kun Dang Pharmaceutical Corp., Fytokem Products

Apr 13, 2021

Search jobs 13-Apr-2021 Plant Derivative Drugs Market Emerging Opportunities, Revenue Analysis and Growth Projections 2021-2028 | Cardax Pharmaceuticals, Chi-Med, Chong Kun Dang Pharmaceutical Corp., Fytokem Products The market data within the whole Plant Derivative Drugs Market research report is displayed in a statistical format to offer a better understanding of the dynamics. The market report makes businesses focus on the more important aspects of the market. It presents a wide-ranging analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behavior, pricing factors, and market performance and estimation throughout the forecast period. Businesses are highly benefited with Plant Derivative Drugs Market research report which brings the market and competitive landscape clearly into the focus and helps make better decisions. The data and information regarding the Industry are taken from trustworthy sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts. Market segmentation has also been performed in detail based on various parameters that include applications, verticals, deployment model, end-user, and geography. Plant derivative drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to growing at a CAGR of 2.60% and is expected to reach USD 502.4 till 2028, in the above-mentioned forecast period. Growing risk of potential side effects of synthetic drugs, such as drug recalls, gastrointestinal upsets,  allergic  reactions, and high price of specialty drugs will assist in encouraging the growth of the market. Get More Insights, Grab Free Sample PDF (350 Pages PDF with All Related Graphs & Charts) @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-plant-derivative-drugs-market Leading Key players: The major players operating in the plant derivative drugs market report Abbott Laboratories, Artecef BV, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax Pharmaceuticals, Chi-Med, Chong Kun Dang Pharmaceutical Corp., Fytokem Products Inc.,Galapagos Nv, Glaxosmithkline, Glenmark Pharmaceuticals Limited, Heterogeneity Llc, Hsrx Biopharmaceutical, Indena, Izun Pharmaceuticals Corp., Lupin Pharmaceuticals Inc., Medigene Ag, Merck & Co. Inc., Merlion Pharmaceuticals, Microbio Co. Ltd., Mycosynthetix Inc., Napo Pharmaceuticals Inc., Novartis International AG, Pfizer, Pharmaceutical Plant Co., Phynova, Sanofi, Santalis Pharmaceuticals, Schwabe Pharmaceuticals, Sequoia Sciences Inc., Sun Pharmaceutical Industries Ltd., Yiviva among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately. This market research report provides a granular analysis of the market share, segmentation, revenue forecasts, and geographic regions of the market. The report comprises a professional and in-depth study on the current state which focuses on the major drivers and restraints for the key players. Plant Derivative Drugs Market Scope and Market Size Plant derivative drugs market is segmented on the basis of types, therapeutics application, dosage types, mode of purchase, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. On the basis of types, the plant derivative drugs market is segmented into terpenes, steroids, glycoside, phenols and others. On the basis of therapeutics application, the plant derivative drugs market is segmented into oncology, dermatology, central nervous system disorders, infectious diseases, cardiovascular diseases, respiratory diseases and others. On the basis of mode of purchase, the plant derivative drugs market is segmented into over the counter and parenteral. On the basis of dosage type, the plant derivative drugs market is segmented into solid oral, liquid, parenteral and others. Solid oral is segmented into tablets, pills, capsule and others. Liquid is segmented into syrups, ointments and others. Parenteral is further segmented into Intravenous, intramuscular, subcutaneous and others. On the basis of end user, the plant derivative drugs market is segmented into Hospitals, specialty clinics, home healthcare and others. For More Insights Get COVID-19-Impact @ https://www.databridgemarketresearch.com/covid-19-impact/global-plant-derivative-drugs-market Healthcare Infrastructure Growth Installed Base and New Technology Penetration Plant derivative drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for plant derivative drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the plant derivative drugs market. The data is available for historic period 2010 to 2019. Competitive Landscape and Plant Derivative Drugs market Share Analysis Plant derivative drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to plant derivative drugs market. The market analysis report includes competitive study, production analysis, applications, and region-wise analysis, competitor landscape, consumption and revenue study, cost structure analysis, price evaluation, and revenue analysis up to 2027 Table of Content:

Cardax Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cardax Pharmaceuticals Rank

Cardax Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Cardax Pharmaceuticals founded?

    Cardax Pharmaceuticals was founded in 2006.

  • Where is Cardax Pharmaceuticals's headquarters?

    Cardax Pharmaceuticals's headquarters is located at 2800 Woodlawn Drive, Honolulu.

  • What is Cardax Pharmaceuticals's latest funding round?

    Cardax Pharmaceuticals's latest funding round is Reverse Merger.

  • How much did Cardax Pharmaceuticals raise?

    Cardax Pharmaceuticals raised a total of $2.86M.

  • Who are the investors of Cardax Pharmaceuticals?

    Investors of Cardax Pharmaceuticals include Koffee Korner, Hawaii Angels, Advantage Capital and International Venture Fund.

  • Who are Cardax Pharmaceuticals's competitors?

    Competitors of Cardax Pharmaceuticals include Aquinox Pharmaceuticals, Viridian Therapeutics, Aegerion Pharmaceuticals, Intarcia Therapeutics, Arteriocyte and 15 more.

Compare Cardax Pharmaceuticals to Competitors

A
Altheus Therapeutics

Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

T
Tacere Therapeutics

Tacere Therapeutics, Inc. specializes in the development of both traditional and therapeutics for the treatment of Hepatitis C (HCV). Combining expertise in small molecules, gene medicine, and RNA interference (RNAi), Tacere possesses skill in the screening and identification of both pharmaceutical and biological agents for the treatment of this major unmet medical need.

F
Funxional Therapeutics

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

C
Catena Pharmaceuticals

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.